PHARMATEK · Gastroentérologie

Calculateur de l’indice de stéatose hépatique original

Calculer l’ISH continu original à partir de l’IMC vérifié, de l’ALAT/ASAT contemporaine et des catégories de coefficients publiées explicites.

Révision clinique en cours

La révision clinique doit être complétée.

Cet outil fait partie de la bibliothèque PharmaTek. Son calcul reste indisponible au public jusqu’à la validation de sa formule, de ses limites et de ses sources.

Explorer les outils accessibles

Sources, population et validation

État: clinical-review-pending
Version de la méthode: Lee 2010 original continuous Hepatic Steatosis Index arithmetic v1: HSI = 8 × [ALT (U/L) / AST (U/L)] + BMI (kg/m²) + 2 when the independently established original-model sex category is female + 2 when independently established diabetes mellitus is present; male and diabetes-absent coefficients are zero; raw continuous output only
Population: Adults for whom applicability of the original Korean health-checkup source context is independently established. The original cross-sectional study included 10,724 subjects: 5,362 ultrasonography-defined NAFLD cases and age- and sex-matched controls, randomly assigned to derivation and validation cohorts. BMI, the published binary female/male coefficient category, and diabetes mellitus status must be independently verified; ALT and AST must be contemporaneous U/L results from one assessment context with compatible assay identities.
Limites et exclusions: The published lower or upper diagnostic cutoffs, any result category, rule-in or rule-out statement, diagnosis, probability, sensitivity, specificity, imaging recommendation, lifestyle recommendation, prognosis, monitoring, management, treatment, or other clinical decision. · Automatic equivalence between the original ultrasonography-defined historical NAFLD outcome in Korean health-checkup subjects and a modern MASLD definition, pediatric use, or extrapolation to another population or analytical context without independently established applicability. · Inference of the original model's binary female/male coefficient category or diabetes status; substitution of gender identity, another sex-category scheme, impaired fasting glucose, glucose, HbA1c, medication data, or any proxy not present in the published equation. · Reversal of the published ALT/AST ratio to AST/ALT, mismatched or non-contemporaneous aminotransferases, incompatible assay or unit identities, inferred units, silently reinterpreted values, or unverified BMI.

Origine de l’outil PharmaTek

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source: PharmaTek · MDose
Version importée: 4b66536936ed
État de publication: Révision clinique en cours

POURSUIVRE AVEC MDOSE

Un outil. Un premier lien.

Recevez des nouvelles des outils ou discutez d’une collaboration. L’utilisation de PharmaTek reste accessible sans laisser vos coordonnées.

Médecins et partenaires